Wednesday Nov 13
Celgene's Revlimid Makes Stronger Case for European Front-Line Approval
Investors got a first look last week at a research abstract for the so-called MM-020 study of Revlimid in newly diagnosed multiple myeloma and results were as good as Celgene bulls could have hoped for.
Spectrum Pharmaceuticals Announces Completion of Enrollment, in...
The secondary objective is to evaluate the efficacy of Melphalan HCl in this patient population as measured by multiple myeloma response rate , myeloablation, and engraftment.